NEW YORK – Grifols announced Thursday that it has signed a strategic agreement with Swiss laboratory automation firm Inpeco to provide automated instrumentation, robotics, and software to transfusion medicine laboratories.
Barcelona, Spain-based Grifols will complement its portfolio with Inpeco's open automation system FlexLab X, which combines robotics and software. Grifols will combine its analytical technologies with Inpeco's automation solutions to dispatch sample tubes to Grifols analyzers and then route them to refrigerated storage after testing to "further reduce manual intervention while guaranteeing full sample traceability," Grifols said in a statement. The goal is to provide transfusion medicine laboratories with tailored instrumentation, robotics, and software capabilities to modernize their operations and make them more efficient.
The two firms are also exploring areas where their "combined engineering expertise could deliver more value to transfusion medicine laboratories, which could include technologies that focus on sample pooling, analysis, and transport," it said.
"At Inpeco, we believe that end-to-end automation is the key to eliminating errors in diagnostic processes," Inpeco CEO Riccardo Triunfo said in a statement. "Especially in transfusion medicine, where precision is nonnegotiable, our mission is to ensure that labs operate with the highest levels of safety, efficiency, and accuracy. Our partnership with Grifols reinforces this vision, enabling laboratories to modernize their operations with confidence."
Financial and other terms of the deal were not disclosed.
Grifols is a pharmaceutical and diagnostics company focused on plasma-derived medicines and diagnostics for transfusion medicine. Inpeco designs and develops automation systems for clinical laboratories.